Filter Results:
(482)
Show Results For
- All HBS Web (482)
- Faculty Publications (182)
Show Results For
- All HBS Web (482)
- Faculty Publications (182)
Page 1 of 482
Results →
- December 2012 (Revised August 2013)
- Case
BMS-Biocon Research Center: Growing a Joint Research Venture in India
By: Vicki Sato, Sen Chai, Rich Ballenger, Christine Chi, Alexander Down and Ross Leimberg
Bristol Myers Squibb, a multi-national pharmaceutical company, is seeking to globalize its R&D strategy while managing costs. It has formed a joint venture with an Indian company, which has worked well, but now faces a strategic decision on how and whether to continue. View Details
Keywords: Pharmaceuticals; Global Innovation; Research And Development; Biomedical Research; Joint Ventures; India; United States
Sato, Vicki, Sen Chai, Rich Ballenger, Christine Chi, Alexander Down, and Ross Leimberg. "BMS-Biocon Research Center: Growing a Joint Research Venture in India." Harvard Business School Case 613-072, December 2012. (Revised August 2013.)
- 2021
- Working Paper
Which Markets (Don't) Drive Pharmaceutical Innovation? Evidence From U.S. Medicaid Expansions
By: Craig Garthwaite, Rebecca Sachs and Ariel Dora Stern
Pharmaceutical innovation policy involves managing a tradeoff between high prices for new products in the short-term and stronger incentives to develop products for the future. Prior research has documented a causal relationship between market size and pharmaceutical... View Details
Keywords: Pharmaceuticals; Medicaid; Innovation and Invention; Policy; Markets; Research and Development; Pharmaceutical Industry
Garthwaite, Craig, Rebecca Sachs, and Ariel Dora Stern. "Which Markets (Don't) Drive Pharmaceutical Innovation? Evidence From U.S. Medicaid Expansions." NBER Working Paper Series, No. 28755, May 2021.
- 2023
- Working Paper
Scoring and Funding Breakthrough Ideas: Evidence from a Global Pharmaceutical Company
By: Joshua Krieger, Ramana Nanda, Ian Hunt, Aimee Reynolds and Peter Tarsa
We study resource allocation to early-stage ideas at an internal startup program of
one the largest pharmaceutical firms in the world. Our research design enables us to
elicit every evaluator’s scores across five different attributes, before seeing how they
would... View Details
Keywords: Project Selection; Pharmaceuticals; Financing Innovation; Resource Allocation; Innovation and Invention; Research and Development
Krieger, Joshua, Ramana Nanda, Ian Hunt, Aimee Reynolds, and Peter Tarsa. "Scoring and Funding Breakthrough Ideas: Evidence from a Global Pharmaceutical Company." Harvard Business School Working Paper, No. 23-014, August 2022. (Revised November 2023.)
- 2009
- Article
Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era
By: Arthur A. Daemmrich
This article presents a case study of the rise of Pfizer as a leading pharmaceutical company, with a focus on changing relationships between manufacturing technology and R&D between the mid-1940s and the mid-1960s. Pfizer first moved into pharmaceuticals through... View Details
Keywords: Research and Development; Production; Technology; Transformation; Relationships; Success; Organizations; Programs; Chemicals; Alignment; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era." History and Technology 23, no. 3 (2009): 237–256.
- Article
Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research
By: Jeffrey Furman, Margaret K. Kyle, Iain Cockburn and Rebecca M. Henderson
Furman, Jeffrey, Margaret K. Kyle, Iain Cockburn, and Rebecca M. Henderson. "Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research." Annales d'économie et de statistique, nos. 79-80 (July–December 2005).
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,... View Details
Keywords: Safety; Industry Growth; Marketing; Research and Development; Health Testing and Trials; Economics; Pharmaceutical Industry; United States
Emmons, Willis M., III. "Note on Pharmaceutical Industry Regulation." Harvard Business School Background Note 792-002, September 1991. (Revised August 1994.)
- 01 Mar 2011
- News
Fixing What Ails the Drug Industry
In 2008, private investors and the National Institutes of Health plowed more than $100 billion into pharmaceutical research. And yet, “We’re not seeing the new diagnostics, treatments, preventative approaches, and cures that we might have... View Details
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001): 32–59.
- Research Summary
Marketing and Competition in Pharmaceutical Markets
In his research on pharmaceutical markets, Professor King explores how marketing and product differentiation affect competition among firms in the prescription market for anti-ulcer drugs. Four main results emerge from an analysis of antiulcer drug sales from 1977 to... View Details
- October 2005 (Revised January 2021)
- Case
Pharmaceutical Industry in 2005, The
By: John R. Wells and Elizabeth Raabe
The entire pharmaceutical industry faced uncertain times in 2005. Many of the industry's most pressing issues—patent expirations, new drug pipeline development, price pressures, regulatory issues, and political pressures—were long standing. Fundamentally new... View Details
Keywords: Strategy; Research and Development; Framework; Change; Competition; Technological Innovation; Pharmaceutical Industry
Wells, John R., and Elizabeth Raabe. "Pharmaceutical Industry in 2005, The." Harvard Business School Case 706-423, October 2005. (Revised January 2021.)
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca Henderson and Iain Cockburn
Henderson, Rebecca, and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001).
- Research Summary
Current Research
Ian studies extrinsic rewards -- monetary incentives from formal compensation systems, as well as other formal and informal external rewards-- in order to help businesses understand the tensions and tradeoffs inherent in motivating employees. His research takes a... View Details
- Research Summary
Research Interests
Research interests are focused on issues of innovation and productivity as they relate to improved outcomes in biotechnology and pharmaceutical R and D. These span topics from decision-making, organizational structure and communication, to the development of novel... View Details
- December 2005
- Article
Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry
This paper argues that the pharmaceutical industry represents an exciting opportunity to carry out academic research. The nature of the industry allows researchers to answer new questions, develop new methodologies for answering these questions as well as to apply... View Details
Manchanda, Puneet, Dick R. Wittink, Andrew Ching, Paris Cleanthous, Min Ding, Xiaojing J. Dong, Peter S. H. Leeflang, Sanjog Misra, Natalie Mizik, Sridhar Narayanan, Thomas J. Steenburgh, Jaap E. Wieringa, Marta Wosinska, and Ying Xie. "Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry." Marketing Letters 16, nos. 3/4 (December 2005): 293 – 308.
- May 2013
- Teaching Plan
China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise
By: Vicki Sato and Annelena Lobb
Sato, Vicki, and Annelena Lobb. "China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise." Harvard Business School Teaching Plan 613-103, May 2013.
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
Keywords: Mergers and Acquisitions; Growth and Development Strategy; Product Development; Research and Development; Corporate Strategy; Pharmaceutical Industry; United States
Collis, David J., and Troy Smith. "Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc." Harvard Business School Case 707-509, November 2006. (Revised November 2007.)
- 2001
- Chapter
Publicly Funded Science and the Productivity of the Pharmaceutical Industry
By: Rebecca Henderson and Ian Cockburn
U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While... View Details
Keywords: Public Sector; Science-Based Business; Research and Development; Sovereign Finance; Pharmaceutical Industry
Henderson, Rebecca, and Ian Cockburn. "Publicly Funded Science and the Productivity of the Pharmaceutical Industry." In Innovation Policy and the Economy, Volume 1, edited by Adam B. Jaffe, Josh Lerner, and Scott Stern, 1–34. MIT Press, 2001.
- 06 Sep 2022
- Research & Ideas
Curbing an Unlikely Culprit of Rising Drug Prices: Pharmaceutical Donations
fund them. New research from Harvard Business School and Harvard Kennedy School professor Leemore Dafny suggests that many pharmaceutical companies may find it highly profitable to fund these... View Details
- Research Summary
Research Summary
By: Leslie A. Perlow
There has been tremendous change in the workplace — ubiquitous technology, 24/7 globalization, hyper-efficiency and now significant changes in work location. Professor Perlow’s research explores the implications for the ways we work and live, and what we can do to... View Details
- September 2019
- Case
Celgene: Business Development and Distributed Research
By: Peter Barrett and Kareem Reda
This case looks at the deal-making process between Celgene, a large publicly traded pharmaceutical company, and Agios, an early-stage biotech company. The framework of a potential deal is explored and the potential road-blocks to Agios’ profitability are discussed. ... View Details
Keywords: Negotiation Deal; Alliances; Collaborative Innovation and Invention; Research; Pharmaceutical Industry; Pharmaceutical Industry
Barrett, Peter, and Kareem Reda. "Celgene: Business Development and Distributed Research." Harvard Business School Case 620-014, September 2019.